U.S. Stock Market Overview: U.S. stock futures declined on Monday following mixed movements in the previous session, with major indices showing slight losses ahead of key economic events, including a speech by Federal Reserve Chair Jerome Powell at the Jackson Hole Symposium.
Retail Earnings Focus: Investors are closely watching earnings reports from major retailers like Walmart, Target, Lowe’s, and Home Depot this week, as 82% of S&P 500 companies that reported so far have exceeded expectations.
Economic Indicators: Recent economic data showed a 0.5% increase in retail sales for July, but consumer sentiment dropped to 58.6 in August, indicating potential weaknesses in consumer confidence amidst inflation concerns.
Market Reactions and Predictions: Analysts express cautious optimism regarding interest rate cuts, while some criticize government officials for influencing monetary policy. Additionally, there are predictions about potential legal challenges to former President Trump's tariffs, which could impact future economic conditions.
ALLR
$1.07+Infinity%1D
Analyst Views on ALLR
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ALLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLR is 9.25 USD with a low forecast of 9.25 USD and a high forecast of 9.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.060
Low
9.25
Averages
9.25
High
9.25
Current: 1.060
Low
9.25
Averages
9.25
High
9.25
Ascendiant
NULL -> Buy
initiated
$9
2025-07-28
Reason
Ascendiant
Price Target
$9
2025-07-28
initiated
NULL -> Buy
Reason
Ascendiant initiated coverage of Allarity with a Buy rating and $9 price target. The firm sees large market opportunities for the company's DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.
About ALLR
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
